Allelic deletions of multiple chromosome 17q loci in sporadic ovarian cancer of epithelial origin suggest that inactivation of tumor suppressor gene(s) in these regions may be important for ovarian tumorigenesis. To further de®ne the pattern of allelic imbalance in epithelial ovarian tumors of dierent histologies, a PCR-based assay was used to assess loss of heterozygosity (LOH) of polymorphic markers representative of TP53, BRCA1, NME1 and GH1, and region 17q23-25. LOH was observed for at least one marker in 68% of malignant tumors (n=60) and in 18% tumors of borderline malignancy (n=11), but not in benign tumors (n=5). The highest frequency of LOH in malignant tumors (64%) was observed with D17S801 on 17q25. Ten of 39 malignant ovarian tumors displaying LOH of at least one 17q marker, displayed a LOH pattern enabling the determination of a minimal region of overlapping deletion de®ned by D17S795 and D17S801. One borderline tumor also displayed an interstitial LOH pattern that overlapped this 17q25 minimal region of deletion. The histologies of malignant tumors displaying a pattern indicative of interstitial 17q deletions were of the endometrioid, clear cell and mucinous epithelial types. As the minimal region of overlap de®ned by these tumors overlap regions deleted in malignant tumors of all histologic types, and in a tumor of borderline malignancy, the 17q25-tumor suppressor may be implicated in the development of all types of epithelial ovarian tumors.
Introduction
Molecular genetic analysis strongly suggests a signi®-cant role for chromosome 17 in the pathogenesis of human epithelial ovarian carcinomas. Loss of heterozygosity (LOH) studies have revealed that allelic imbalance of chromosome 17 loci occurs frequently in malignant ovarian tumors (Eccles et al., 1990; Lee et al., 1990; Russell et al., 1990; Sato et al., 1991; Foulkes et al., 1993; Phillips et al., 1993; Tavassoli et al., 1993) . As the loss of alleles suggest the presence of tumor suppressors implicated in ovarian carcinogenesis, the accurate de®nition of such regions of LOH will aid in the isolation of genes involved in ovarian tumorigenesis. However, in ovarian cancer a signi®cant proportion of tumors display loss of all informative polymorphic loci, strongly suggestive of a loss of an entire chromosome 17 homolog (Foulkes et al., 1993; Tavassoli et al., 1993; Pierretti et al., 1995; Papp et al., 1996) . This conclusion is supported by a recent cytogenetic survey showing the frequent occurrence of reduction to monosomy (due to non-dysjunction, with or without duplication), and the uncommon occurrence of translocations, deletions and isochromosomes in ovarian tumors (Mertens et al., 1997) .
Both chromosome 17 arms contain genes implicated in ovarian tumorigenesis. These genes include the TP53 tumor suppressor at 17p13 (Marks et al., 1991; Okamoto et al., 1991; Tsao et al., 1991; Eccles et al., 1992; Milner et al., 1993) , the HER2/neu oncogene at 17q12 (Slamon et al., 1989) , the BRCA1 breast-ovarian cancer susceptibility gene at 17q12 (Miki et al., 1994; Merajver et al., 1995) , and the NME1 tumor metastasis marker on 17q21-23 (Viel et al., 1995; Scambia et al., 1996; Schneider et al., 1996) . Somatic mutations and increased expression of TP53 have been more often reported in high grade and later stage tumors (Berchuck et al., 1994; Kupryjanczyk et al., 1993) . Increased expression of HER2/neu accompanied with or without gene ampli®cation is also a feature of some tumors of high grade and late stage (Slamon et al., 1989) . Recently, HER2/neu gene ampli®cations has been found to occur only in the subset of ovarian tumors which display LOH of a number of chromosome 17 loci (Papp et al., 1996) . In some studies, an increased expression of NME1 has been associated with a more aggressive phenotype (Leary et al., 1995; Mandai et al., 1995; Schneider et al., 1996) , although this association remains controversial (Harlozinska et al., 1996) . These data are all consistent with the high frequency of LOH chromosome 17 loci harboring these genes in tumors of high grade and stage.
A complex LOH pattern consistent with partial loss of chromosome 17 in ovarian tumors has also been reported. The minimal regions of overlapping deletions have been mapped to 17p13 (Tsao et al., 1991; Phillips et al., 1996; Wiper et al., 1998) , 17q12 , 17q21-23 (Jacobs et al., 1993; Yang-Feng et al., 1993; Godwin et al., 1994) , and 17q25 (Kalikin et al., 1997) . LOH studies provide evidence in support of an additional tumor suppressor which lies distal to TP53 (Wales et al., 1995; Phillips et al., 1996; Schultz et al., 1996; Werthiem et al., 1996; Wiper et al., 1998) . The poor correlation between LOH of chromosome 17 and mutation status of TP53 (Phillips et al., 1996; Sakamoto et al., 1996; Wiper et al., 1998) would support the hypothesis that other 17p loci may be implicated in ovarian tumorigenesis. The LOH analysis of 17q in malignant tumors has provided evidence in support of at least three tumor suppressors all located distal to BRCA1 and which exclude NME1 (Jacobs et al., 1993; YangFeng et al., 1993; Godwin et al., 1994; Kalikin et al., 1997) . At least one tumor suppressor on 17q arm located proximal to BRCA1 has been described in tumors of borderline malignancy (low malignancy potential) . As the minimal regions of LOH observed in malignant tumors exclude known genes implicated in tumorigenesis, the data imply that there are additional tumor suppressors implicated in ovarian tumorigenesis and that the inactivation of one or more of these gene(s) may be important for the etiology of ovarian cancer.
Despite allelotyping of 17q in ovarian tumors, the identi®cation of novel tumor suppressors has remained elusive. This can be attributed to the observation that interstitial chromosome 17 loss is not reported frequently in a large majority of ovarian tumors which may in part be due to the fact that ovarian tumors are often obtained at an advanced stage of diagnosis. We have examined a large series of ovarian tumors of dierent histologies to further de®ne the chromosome 17 LOH pattern. We have focused our studies on the long arm of chromosome 17q in order to establish which histological types would most likely yield mapping information for future studies focusing on the cloning of novel 17q tumor suppressors.
Results

LOH analysis in ovarian tumors grouped according to pathology
Forty-three of 76 (57%) tumors displayed LOH of at least one polymorphic marker on chromosome 17. Representative examples of the LOH analysis are shown in Figure 1 and summarized schematically in Figure 2 . LOH of at least one informative marker was observed in 41 of 60 malignant tumors (Table 1) and two of 11 tumors of borderline malignancy but not in ®ve benign tumors. The highest frequency of LOH in malignant tumor specimens was observed with the 17q25 marker D17S801. Ten malignant tumor samples displayed an LOH pattern consistent with partial loss of 17q enabling the determination of the smallest region of overlapping deletion de®ned by D17S795 and D17S801. This conclusion is drawn by the analysis of tumor specimens exhibiting the smallest region of LOH such as specimen 986T that displayed LOH of D17S795 and retention of D17S578 and D17S801, and specimen 4093T that displayed LOH of D17S801 and retention of D17S795 and D17S937.
The minimal region of overlap deduced by the analysis of the malignant tumors overlaps the minimal region of deletion observed in the LOH analysis of 2955T, a tumor of borderline malignancy. This specimen displayed LOH of D17S795 but retention of D17S578 and D17S801 (Figures 1 and 2 ). However, in another tumor of borderline malignancy, 1499T, LOH of markers representative of BRCA1 and GH1 were observed ( Figure 2 ). As the analysis of D17S578 was not informative for this tumor specimen, another interpretation of this data suggests that D17S578 and D17S795 de®ne the minimal region of overlap.
LOH of TP53 was only observed in malignant tumor specimens. LOH was observed in 22 of 50 (44%) tumors informative for this marker and this frequency is lower than that observed for any 17q marker. Twenty of the 22 tumors displaying LOH of TP53 also displayed LOH of at least one 17q marker. However, none of these samples displayed an LOH pattern consistent with partial loss of the 17q arm ( Figure 2 ).
LOH analysis with respect to histological type
LOH of chromosome 17 markers was analysed with respect to tumors grouped according to histological types. LOH of at least one informative marker was observed in malignant tumors representative of each histological type (Table 1 ). The serous tumors displayed three patterns of LOH compatible with loss of the TP53 locus, loss of part or the whole 17q arm or loss of both the TP53 locus and the 17q arm ( Figure  2 ). The LOH pattern displayed by the analysis of the malignant serous tumors enabled the determination of a minimal region of overlapping deletion de®ned by BRCA1 and D17S937. The majority of malignant endometrioid tumors exhibited a LOH of at least one marker informative for chromosome 17. These tumors displayed two LOH patterns compatible with loss of part or the whole 17q arm or loss of both the TP53 locus and the 17q arm. The TP53 locus was informative for all 11 samples and there was no evidence for LOH of the TP53 locus independent of LOH of any 17q marker. This is in contrast to the results observed with the serous tumors, although there were fewer endometrioid tumors for analysis. The LOH pattern displayed by endometrioid tumors enabled the determination of a minimal region of overlapping deletion de®ned by D17S578 and D17S801. A clear cell carcinoma displayed LOH of markers distal to D17S351, and a mucinous carcinoma displayed LOH of D17S801 but retention of D17S795 and D17S93. The LOH patterns displayed by these tumors overlap the minimal regions of LOH deduced in the analysis of malignant serous and endometrioid tumors. The LOH patterns exhibited by the undierentiated and mixed cell tumors are consistent with loss of the 17q arm or both arms of chromosome 17. The two tumors of borderline malignancy displaying LOH of chromosome 17 markers were of dierent histologies (Figure 2 ). While the LOH patterns diered, they overlapped those displayed by malignant tumors of dierent histological types.
LOH analysis with respect to tumor grade and stage LOH of chromosome 17 markers was analysed according to tumor grade and stage (Table 1 and Figure 2) . None of the grade 1 tumors displayed LOH of any informative marker. A LOH pattern consistent with interstitial loss of the 17q arm was observed with both grade 2 and 3 tumors. Although there were only 11 endometrioid tumors analysed, ®ve of the eight tumors displaying a LOH pattern consistent with partial or complete LOH of the 17q arm were grade 2 tumors.
Although LOH was observed for tumors representative of dierent stages, no evidence of TP53 loss was observed for stage I tumors (Table 1 and 
Discussion
This study has documented frequent LOH occurring at multiple chromosome 17 loci in unselected epithelial ovarian cancer. In samples displaying loss of at least one chromosome 17q allele, the LOH pattern was consistent with the loss of a complete long arm of chromosome 17. In addition, the frequent LOH of TP53 accompanying LOH of all informative 17q loci suggests that complete loss of an entire chromosome 17 homolog is a frequent event in epithelial ovarian cancer. The high frequency of LOH of 17q loci is in line with the independent reports demonstrating a frequent LOH (ranging from 30 to 89%) of all polymorphic markers on chromosome 17 (Foulkes et al., 1993; Tavassoli et al., 1993; Pieretti et al., 1995; Papp et al., 1996) .
The LOH pattern observed in the analysis of 17q markers distinguishes histologic types of epithelial ovarian cancer. The rarity of interstitial loss of chromosome 17 loci observed in the present study contributes to the growing body of literature demonstrating that reduction to homozygosity is a common occurrence in the serous histologic type of ovarian tumors (Foulkes et al., 1993; Pierretti et al., 1995; Papp et al., 1996) . Pierreti et al. (1995) postulated that the loss of an entire chromosome 17 homolog in serous tumors confers a selective advantage during progression such that this event would bring about the development of a highly malignant tumor. This model would be consistent, in part, with the high frequency of chromosome 17 LOH observed in high grade and advanced stage tumors of serous histology. While Pierretti et al. (1995) reported an overall dierence in LOH of 17p versus 17q markers in endometrioid and mucinous tumors, the LOH patterns displayed by each tumor type was not described and therefore comparisons with the present study cannot be made. The observation by Papp et al. (1996) that LOH across multiple chromosome 17q alleles is infrequent in tumors of endometrioid, mucinous and clear cell histology are comparable with those described in the present study. However, LOH patterns observed for the endometrioid and mucinous tumors diered. The authors described that endometrioid tumors displayed non-overlapping regions of deletions, where in one case one region of deletion overlapped that observed in mucinous samples. The lower frequency of LOH for 17q25 markers in these two studies (Pieretti et al., 1995; Papp et al., 1996) may be a re¯ection of the lack of representation of markers used to represent the distal end of 17q. Kalikin et al. (1997) did not report the histology of the ovarian tumors which displayed loss of 17q25 loci and thus a comparison based on cell type could not be commented upon. The dierences in the chromosome 17 LOH pattern observed with the histological types of epithelial ovarian cancer may re¯ect dierences in molecular genetic events leading to each tumor type. The fraction of ovarian tumor samples displaying a LOH pattern consistent with partial loss of 17q enabled the determination of a minimal region of deletion on 17q25 de®ned by D17S795 and D17S801 (Figure 3 ). This minimal region of overlapping deletions contains the marker (D17S801) that displayed the highest frequency of LOH in our study. This minimal region of LOH is distinct from that located distal to NME1 and proximal to GH1 described by Jacobs et al. (1993) . However, the region de®ned in the present study overlaps that de®ned by D17S74 and D17S24 as described by Yang-Feng et al. (1993) in which the proximal boundary was further re®ned to exclude GH1 by Godwin et al. (1994) . Our results are also comparable with those of a recent study demonstrating a high frequency of LOH associated with 17q25 loci, D17S722 and D17S937 (Kalikin et al., 1997) . However, the minimal region of deletion determined in the later study is de®ned by D17S722 and D17S802, a marker that has been mapped distal to D17S937 (Figure 3 ). Therefore our results combined with those of the Kalikin et al. (1997) study would suggest that there are at least two tumor suppressor genes implicated in ovarian tumorigenesis.
The order of the markers used in the present analysis of 17q25 (D17S795, D17S801, and D17S937), as well as D17S802 used in the Kalikin et al. (1997) study, have been independently established based on genetic, physical and radiation reduced hybrid maps (Hudson et al., 1995; Dib et al., 1996; Plummer et al., 1997c) . In early studies, D17S722 was arbitrarily placed in the 17q25 region but its order relative to these markers was unknown (Plummer et al., 1997c) . More recent genetic and physical maps of 17q25 establish the markers D17S795-D17S801-D17S722-D17S939-D17S802 in order to centromere to telomere (Risk et al., 1999) as shown in Figure 3 . The placement of D17S937 distal to D17S722 is not inconsistent with this map order as another group has shown no evidence of recombination between D17S939 and D17S937 thus suggesting the close proximity of these two markers (Plummer et al., 1997c) . If the above order of markers is correct then the minimal region of deletion de®ned by our analysis places a tumor suppressor gene proximal to the minimal region of deletion de®ned by the Kalikin et al. (1997) study. However, a recent report by Kalikin et al. (1999) puts into question the assignment of the 17q25 markers as they ordered markers D17S722-D17S801-D17S937-D17S939-D17S802, centromere to telomere. The interpretation of the minimal regions of deletion de®ned by the present study is dicult, as D17S795 was not placed on this alternate map. It would be interesting to establish the LOH pattern of markers D17S801 and D17S795 in the two tumors that de®ned the minimal region of deletion to D17S722 and D17S937 described in the Kalikin et al. (1997) study. The discrepancies in the order of the markers may be attributed to the lack of overlapping physical contigs as both maps contain gaps.
In the present study we contribute to the growing body of evidence attesting to the importance of chromosome 17 in the etiology of epithelial ovarian cancer. Based on the LOH pattern displayed by the group of ovarian tumors and that interstitial LOH pattern was observed more often in tumors of lower grade and earlier stage, it is tempting to speculate that LOH of 17q25 may precede LOH of TP53, and thus that 17q25 tumor suppressor may be inactivated early in the pathway of ovarian tumorigenesis. We propose that the identi®cation of the 17q25 tumor suppressor would be greatly facilitated by concentrating eort on mapping allelic imbalances in non-serous histologic types of ovarian cancer and, in particular, tumors of the endometrioid type. As the minimal region of overlapping deletions de®ned by the analysis of the non-serous types overlaps that seen in the more common serous type, the 17q25 tumor suppressor may also play a role in the etiology of all histological types of epithelial ovarian tumors. However, the low frequency of endometrioid tumors and thus the use of Figure 3 Chromosome 17 ideogram. The order of the polymorhpic markers are presented according to previously published maps (Gyapay et al., 1994; Dib et al., 1996; Hudson et al., 1995; Plummer et al., 1997c) and recent website updates from the Genome Database (http://gdbwww.gdb.org). The order of the markers mapped to 17q25 is ambiguous (see Discussion). The arrowhead is placed to indicate the minimal region of imbalance deduced by the LOH analysis of ovarian tumors LOH analysis as a tool for establishing the minimal region of LOH for the future identi®cation of tumor suppressor will continue to be challenging in the absence of a consortium for this purpose. Recent LOH studies have indicated the presence of a tumor suppressor on 17q24-25 in breast cancer (Cornelis et al., 1993; Cropp et al., 1993; Kalikin et al., 1996; Plummer et al., 1997b; Phelan et al., 1998) , and in squamous cell carcinomas of the esophagus (von Breven et al., 1998) . In the latter study, the highest frequency of LOH was observed in D17S801 in a series of sporadic tumors, and this locus overlaps the 17q24-25 interval which showed a signi®cant linkage to the tylosis-associated cancer susceptibility gene (TOC) (Kelsell et al., 1996) . Recently, the location of the TOC was further de®ned by haplotype analysis to an interval of approximately 1 cM that includes D17S801 (Risk et al., 1999) . The minimal region of deletion de®ned by the present study overlaps this interval. In a recent cytogenetic survey of 3185 neoplasms (which included 304 ovarian carcinomas), carcinomas of the kidney, ovary and, head and neck, neurological tumors, and testicular germ cell tumors displayed a clear increase in loss of bands 17q23-qter (Mertens et al., 1997) . A functional assay was used to demonstrate the presence of a growth suppressor gene on 17q24-25 in breast cancer cell line MCF-7 (Plummer et al., 1997a) . The cloning of the genes responsible for these cancers however will require improved maps of 17q25, and thus it is critical that eort is made to resolve the inadequate mapping of this region of the genome in parallel to LOH mapping studies of tumor tissue.
Materials and methods
Clinical material
Tumor tissue and patient-matched normal peripheral lymphocytes were obtained from 76 participants at the time of surgery from patients at the Montreal General Hospital (unique patient identi®er followed by letter T) and the CHUM-HoÃ pital Notre Dame (designated by a letter code followed by a unique patient identi®er). Histology was determined by pathological examination using criteria established by the International Federation of Gynecologists and Oncologists (FIGO). Five specimens (687T, 968T, 1014T, 3095T, and 3229T) were obtained from recurrent tumors in patients previously treated with platinum-based chemotherapy.
DNA extraction
DNA was extracted from solid tumors, snap frozen in liquid nitrogen at the time of resection, and from peripheral lymphocytes according to the method described previously (Lounis et al., 1994) .
LOH analysis
A PCR-based assay was used to allelotype polymorphic markers representing speci®c chromosome 17 loci (see Table  1 ). The TP53 marker has been described in Hahn et al. (1993) and the remaining makers have been described in Genome Data Base (http:/gdbwww.gdb.org). LOH analysis of BRCA1 was performed using intronic marker D17S855, and when not informative for this marker intronic markers, D17S1322 and D17S1323, were used. D17S351 is located at region 17q21-23 and likely distal to NME1 (Borrow et al., 1991) . PCR was performed in 25 ul volume containing 100 ng of genomic DNA, 1 mCi of 35 S[dATP], 16PCR buer (Pharmacia). The PCR conditions were 958C for 15 s, 558C for 15 s, and 728C for 30 s during 30 cycles. The reaction products were diluted 1 : 2 with stop buer (90% formamide, 10 mM EDTA, 10% bromophenol blue, 10% xylene cyanol) and heated at 948C for 10 min prior to loading on a 5% polyacrylamide denaturing gel. Gels were dried at 808C and autoradiographed 1 ± 3 days (Hyper®lm MP, Amersham Life Science).
LOH (allelic imbalance) was scored based on the absence or a dierence in the relative intensity of alleles in tumor DNA compared to normal DNA. The LOH analysis of BRCA1 presented in Table 1 , and Figure 2 , represent the combined analysis of the three intronic markers representing this locus. All samples that de®ne regions of LOH at individual loci were analysed at least twice in independent LOH assays.
